KSI-301 + Aflibercept
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Macular Edema
Conditions
Macular Edema, Retinal Vein Occlusion
Trial Timeline
Sep 25, 2020 โ Jan 19, 2023
NCT ID
NCT04592419About KSI-301 + Aflibercept
KSI-301 + Aflibercept is a phase 3 stage product being developed by Kodiak Sciences for Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT04592419. Target conditions include Macular Edema, Retinal Vein Occlusion.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04964089 | Phase 3 | Completed |
| NCT04611152 | Phase 3 | Terminated |
| NCT04603937 | Phase 3 | Terminated |
| NCT04592419 | Phase 3 | Completed |
| NCT04049266 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Macular Edema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVT aflibercept + Sham SC + SC CLS-TA | Clearside Biomedical | Phase 2 | 44 |
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| 4 mg CLS-TA + Sham + IVT aflibercept | Clearside Biomedical | Phase 2 | 44 |
| suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin | Clearside Biomedical | Phase 3 | 69 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 1 | 28 |
| FYB203 2 mg (0.05 mL of 40 mg/mL) | Formycon AG | Approved | 77 |
| FYB201 0.5 mg (0.05 mL of 10 mg/mL) | Formycon AG | Approved | 77 |
| UBX1325 injection 50 ฮผL + EYLEAยฎ (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 2 | 44 |
| Aflibercept + foselutoclax | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 1 | 25 |
| CT-P42 + Eylea | Celltrion | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Fovistaยฎ + bevacizumab + ranibizumab + aflibercept | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |